Monoclonal antibodies for metastatic colorectal cancer treatment (Cetuximab and/or Panitumumab)

Summary

The State Health Insurance Fund under Lithuania’s Ministry of Health is purchasing monoclonal antibodies Cetuximab and/or Panitumumab for metastatic colorectal cancer treatment. The procurement has two lots: Lot 1 covers one of the two medicines for new patients, while Lot 2 covers Panitumumab for patients continuing treatment. The listed maximum quantities are up to 1,077,300 mg of Cetuximab or 491,400 mg of Panitumumab in Lot 1, and up to 225,000 mg of Panitumumab in Lot 2; orders will be placed according to actual need, so these maximum quantities are not guaranteed purchases.